Drug carrier having self-assembled 3-D nucleic acid nanostructure

Patent metadata

Field	Value
Publication number	US-11446254-B2
Application number	US-201916538109-A
Country	US
Kind code	B2
Filing date	Aug 12, 2019
Priority date	Jul 23, 2014
Publication date	Sep 20, 2022
Grant date	Sep 20, 2022

Abstract

The present invention relates to a molecule delivery technology and a carrier technology, which may selectively deliver a material to a desired specific cell and living tissue. The present invention may be utilized in the field of a drug carrier which effectively delivers an imaging probe and a therapeutic agent to an affected part.

First claim

The invention claimed is:

1. A method of in vivo delivering a pharmaceutically active ingredient to cancer tissue, comprising:
administering a self-assembled 3-D nucleic acid nanostructure as a pharmaceutically active ingredient carrier to a subject in need thereof,
wherein the self-assembled 3-D nucleic acid nanostructure comprises:
double strand nucleic acids; and
single strands form the sides of the self-assembled 3-D nucleic acid nanostructure,

wherein the pharmaceutically active ingredient carrier has an L-DNA triangular prism structure composed of 5 strands of L-DNA self-assembled from the combination of:
i) a single strand of an L-DNA nucleotide sequence of SEQ ID NO:15;
ii) a single strand of an L-DNA nucleotide sequence of SEQ ID NO:16;
iii) a single strand of an L-DNA nucleotide sequence of SEQ ID NO:17;
iv) a single strand of an L-DNA nucleotide sequence of SEQ ID NO:18; and
v) a single strand of an L-DNA nucleotide sequence of SEQ ID NO:19, and
wherein the pharmaceutically active ingredient carrier does not comprise a targeting ligand for the tissue.

2. The method of claim 1 , wherein the pharmaceutically active ingredient is an anticancer agent.

3. The method of claim 1 , wherein the pharmaceutically active ingredient encapsulated is within the nucleic acid nanostructure or bonded to the backbone of the nucleic acid nanostructure, and thereby delivered to the tissue.

4. A method of in vivo delivering an anticancer agent comprising:
administering a pharmaceutical composition comprising:
a self-assembled 3-D nucleic acid nanostructure as an anticancer agent carrier to carry the anticancer agent to a subject in need thereof,
wherein the self-assembled 3-D nucleic acid nanostructure comprises:
double strand nucleic acids; and
single strands form the sides of the self-assembled 3-D nucleic acid nanostructure,

wherein the anticancer agent carrier has an L-DNA triangular prism structure composed of 5 strands of L-DNA self-assembled from the combination of:
i) a single strand of an L-DNA nucleotide sequence of SEQ ID NO:15;
ii) a single strand of an L-DNA nucleotide sequence of SEQ ID NO:16;
iii) a single strand of an L-DNA nucleotide sequence of SEQ ID NO:17;
iv) a single strand of an L-DNA nucleotide sequence of SEQ ID NO:18; and
v) a single strand of an L-DNA nucleotide sequence of SEQ ID NO:19, and
wherein the anticancer agent carrier does not comprise a targeting ligand for the tissue.

5. The method of claim 1 , wherein each single strand is connected by linker.

6. The method of claim 2 , wherein the anticancer agent is doxorubicin.

7. The method of claim 4 , wherein the anticancer agent is doxorubicin.

8. The method of claim 1 , the self-assembled 3-D nucleic acid nanostructure is mixed with a pharmaceutical acceptable carrier selected from the group consisting of gum acacia, methyl hydroxybenzoate, and propyl hydroxybenzoate.

9. The method of claim 4 , the self-assembled 3-D nucleic acid nanostructure is mixed with a pharmaceutical acceptable carrier selected from the group consisting of gum acacia, methyl hydroxybenzoate, and propyl hydroxybenzoate.

Assignees

• Korea Inst Sci & Tech

Inventors

• Ahn Dae Ro
• Kim Se Hoon
• Kim Kyoung Ran
• Kim Hyo Young
• Lee Yong Deok

Classifications

• A61K31/704

  attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title

• A61K49/0043

  Fluorescein, used in vivo · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/713

  Double-stranded nucleic acids or oligonucleotides · CPC title

• A61K49/0032

  Methine dyes, e.g. cyanine dyes · CPC title